stand welcome illumina earn conference call operator instruction turn call host begin investor afternoon everyone welcome earn call second quarter call today review financial result release close market offer commentary commercial activity host question answer session chance review earn release find investor relation section website illumina participate illumina today president chief executive officer chief financial officer provide update state illumina business review financial result call record audio portion archive investor section website intent forward look statement regard financial result commercial activity make today call protect private security litigation reform forward look statement subject risk uncertainty actual event result differ materially project discuss forward look statement base upon current available information illumina assume obligation update statement better understand risk uncertainty could cause actual result differ refer document illumina file security exchange commission include illumina recent form turn call chief executive good afternoon everyone illumina deliver revenue billion represent year year growth significantly exceed expectation across geographic region market segment clinical market include oncology reproductive health genetic disease test expand reimbursement coverage increase patient awareness grow sequence application enter clinic ramp population sequence program contribute robust growth research business additionally genomic surveillance emerge critical tool global fight pandemic country illumina platform surveillance look forward momentum global surveillance infrastructure backbone durable global genomic epidemiology capability combat future outbreak include transmission antimicrobial resistance second consecutive quarter record instrument sale revenue year year quarter highest instrument backlog since launch look performance platform high throughput portfolio continue spectacular achieve highest order volume since launch demand high throughput sequence capacity continue expand half order come customer high throughput additionally customer continue system higher rate meet demand oncology test genetic disease test population sequence program throughput platform continue drive growth record placement strength almost three time output enable excite application customer like cold spring harbor single cell analysis clinical customer drive placement record shipment trend toward decentralization clinical sequence outside benchtop platform also excellent quarter instrument revenue year year ship instrument quarter prior quarter last five year record demand drive core business emerge area like genetic screen surveillance turn clinical research apply segment sequence consumables revenue million year year drive demand clinical research segment start clinical business focus market access collaboration expand reimbursement power exist test provider benefit patient around world billion cover life globally across oncology demonstrate expertise impact illumina market access drive coverage also enormous opportunity clinical segment oncology test largest market segment record third consecutive quarter outstanding year year growth customer announce additional offer therapy selection test therapy selection expand reimbursement comprehensive genomic profile fuel shift small large panel life cover additional indication approve customer enter oncology test field exist customer like expand footprint oncology illumina comprehensive genomic profile assay achieve sample milestone additional customer year across country addition last year test emerge driver future growth oncology segment positive reimbursement decision customer multiple approach enter market also excite pharma invest base clinical trial bring prove drug early stage disease improve patient outcome reproductive health consumable shipment continue benefit revise guideline expect would cover approximately three million pregnancy already surpass milestone expect coverage continue expand also make progress outside ensure expect family access example national coverage implement additionally continue growth mark solution next generation genomic adopt solution broaden access expand parent southeast genetic disease test deliver another outstanding quarter drive reimbursement coverage increase across lower sequence price enable accelerate shift exomes genome quarter also promise research guideline recognize diagnostic yield effectiveness whole genome sequence genetic disease child hospital state publish result project baby bear groundbreaking program showcase significant benefit rapid whole genome sequence decrease time diagnosis healthcare spend critically infant patient change care diagnosis enable rapid whole genome sequence protocol available grow network hospital partner hospital network across country turn research apply segment strong year year sequential growth momentum population genomics program continue grow operate full scale thousand genome week also multiple initiative ramp internationally provide ongoing pipeline opportunity expect revenue different initiative second half year spatial single cell approach gain traction many research segment drive high intensity sequence success illumina partnership company time enable novel discovery expand application enter clinic emergence delta variant renew focus heighten awareness genomic surveillance fight future pathogen launch sample assay expand quarter demonstrate continue commitment provide workflow instrument bioinformatics meet challenge work government test surveillance initiative country effort drive increase consumable revenue relative time expect consumable revenue second half remain relatively steady first half philanthropic effort work ensure country high need surveillance limit resource also access consumables earlier week announce donation million sequence capability include molecular diagnostic reference laboratory hospital enable surveillance epicenter second wave hand call provide brief update grail grail launch first kind multi cancer screen test make test available employee encourage positive feedback receive excite promise genomics come fruition oncology screen commit support company innovate space share late remain commit close competitive deal believe acquisition illumina uniquely position help save thousand life turn call chief financial outline second quarter revenue exceed expectation grow year year billion drive growth sequence growth microarrays first time company history total quarter sequence revenue exceed billion grow sequentially billion represent total revenue core business continue accelerate across region quarter drive growth clinical strong demand research customer particularly impact pandemic second quarter continue resume expand sequence sequence consumables revenue grow year year million lead record consumable shipment robust demand drive flow cell sequence instrument revenue grow year year million reflect another quarter significant strength across instrument category shipment double second quarter drive continue adoption high throughput customer throughput system shipment reach high drive record shipment demand since launch ship illumina customer revenue contribution surveillance test exceed expectation contribute approximately million sequence consumables revenue million incremental instrument revenue sequence service revenue also higher expect grow year year million primarily approximately million onetime revenue recognize royalty receive relate patent litigation settlement move regional result revenue region million grow compare prior year period revenue growth region drive record sequence product revenue relate demand clinical oncology test genetic disease test regional performance also drive strength genetic disease research population genomic initiative contribution surveillance test deliver revenue million represent growth year year performance drive recovery research acceleration clinical business include record quarter genetic disease test momentum expand market access reimbursement surveillance test also contribute strong performance region greater revenue million represent growth year year continue strength sequence lead clinical growth region sequence instrument shipment double year year drive grow demand hospital give superior ease accuracy quality output illumina finally revenue million grow year year drive sequence consumables revenue growth across clinical application reproductive health genetic disease test strong utilization research customer expect revenue decrease sequentially time fiscal year purchase normal seasonality first quarter move gross margin operate expense highlight result include stock base compensation encourage review reconciliation measure find today release supplementary data available website gross margin improve sequentially basis point mainly favorable utilization strong demand onetime revenue patent litigation settlement year year basis gross margin increase basis point increase leverage higher volume positive impact patent litigation settlement partially offset product operate expense million increase million sequentially higher compensation relate expense increase project relate spend lower expect time certain investment shift second half expect operate expense million year year increase performance base compensation expense headcount growth additional investment support growth business operate margin compare first quarter operate margin better expect higher revenue favorable gross margin drive higher volume onetime patent litigation settlement expense million flat sequentially million lower year year expect year year decline primarily lower interest income short term investment reposition investment portfolio anticipate fund grail acquisition rate decrease last quarter expense recognize first quarter certain foreign subsidiary earn longer indefinitely reinvested decrease rate year year higher earn jurisdiction lower rate second quarter income million dilute share income million dilute share move cash flow balance sheet item cash flow operation million include million continuation payment make grail pursuant merger agreement compare last quarter drive revenue linearity second quarter capital expenditure million free cash flow million repurchase common stock second quarter quarter approximately billion cash cash equivalent short term investment second quarter million repay outstanding principal convertible note mature weight average dilute share count quarter approximately million move guidance expect full year revenue grow range billion billion midpoint represent increase approximately billion compare full year midpoint revenue guidance range expect total sequence revenue grow approximately year year drive accelerate strength core business higher expect contribution surveillance test expect operate margin approximately reflect higher revenue expectation ongoing commitment continue innovation continue maintain focus improve core business operate margin leverage time expect rate increase approximately basis point prior year higher previous expectation expect earn share range earn share range move third quarter expect revenue increase approximately year year expect earn share range earn share range hand call back final remark chief executive clear strong first half result illumina customer fire clinical market grow expand reimbursement give patient access exist genomic test evidence generation bring genomic application clinic oncology cancer patient access therapy selection emerge early cancer detection test drive significant long term growth sequence genetic disease test speed diagnosis treatment benefit rapid offer catalyze awareness adoption coverage expand dramatically still significant need internationally represent tremendous growth opportunity research fund overall investor capital deployment life science continue incredibly robust drive innovation case sequence decade come single cell spatial approach complex problem drive larger scale novel research clinical solution benefit population genomics program national health system drive government take initiative broaden reach sequence across globe surveillance initiative foundation permanent global genomic epidemiology infrastructure illumina play central role advancement genomics human health proud execution fantastic around world incredible time field excite technology road development time company honor work alongside colleague fulfill illumina instrumental role improve human health unlock power genome invite operator open